PMID: 16613552Apr 15, 2006Paper

The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders

CNS & Neurological Disorders Drug Targets
Pierre SokoloffChristian Gross

Abstract

The role of the D(3) receptor has remained largely elusive before the development of selective research tools, such as selective radioligands, antibodies, various highly specific pharmacological agents and knock-out mice. The data collected so far with these tools have removed some of the uncertainties regarding the functions mediated by the D(3) receptor. The D(3) receptor is an autoreceptor that controls the phasic, but not tonic activity of dopamine neurons. The D(3) receptor, via regulation of its expression by the brain-derived neurotrophic factor (BDNF), mediates sensitization to dopamine indirect agonists. This process seems responsible for side-effects of levodopa (dyskinesia) in the treatment of Parkinson's disease (PD), as well as for some aspects of conditioning to drugs of abuse. The D(3) receptor mediates behavioral abnormalities elicited by glutamate/NMDA receptor blockade, which suggests D(3) receptor-selective antagonists as novel antipsychotic drugs. These data allow us to propose novel treatment options in PD, schizophrenia and drug addiction, which are awaiting evaluation in clinical trials.

Citations

Nov 7, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Gerhard GrossKarla U Drescher
Mar 14, 2013·Psychopharmacology·Ciara McCabePhilip J Cowen
Aug 11, 2010·Current Psychiatry Reports·Kyle M Kampman
Mar 25, 2010·Neuroscience Bulletin·Ming-Lei GuoJohn Q Wang
Jun 25, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Shinichiro NakajimaAriel Graff-Guerrero
Jun 21, 2005·Neuropharmacology·Bernard Le FollPierre Sokoloff
Jun 1, 2005·Trends in Pharmacological Sciences·Bernard Le Foll, Steven R Goldberg
Jun 16, 2010·Experimental and Clinical Psychopharmacology·Gregory J MaddenStephen C Fowler
May 13, 2009·Acta Pharmacologica Sinica·Zheng-xiong XiEliot L Gardner
Dec 24, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ragy R GirgisMark Slifstein
Oct 28, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David J G WatsonKevin C F Fone
Jan 16, 2008·Behavioural Pharmacology·Bernard Le FollSteven R Goldberg
Aug 29, 2012·Journal of Clinical Psychopharmacology·Shoko TsuchimineSunao Kaneko
May 9, 2012·Parkinson's Disease·Brendan J KelleyPeter Chiu
Feb 10, 2010·Journal of Psychopharmacology·Amanda E HigleyEliot L Gardner
Nov 1, 2007·Journal of Dual Diagnosis·Ivan D Montoya, Frank Vocci
Jan 2, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·David H ZaldRobert M Kessler
Sep 11, 2008·Pharmacogenomics·Bk ThelmaArun Kumar Tiwari
Oct 6, 2005·Psychopharmacology·Bernard Le Foll, Steven R Goldberg
Sep 4, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Doris PayerIsabelle Boileau
Aug 11, 2010·European Journal of Nuclear Medicine and Molecular Imaging·Vesna SossiRaúl de la Fuente-Fernández
Oct 16, 2014·Neural Regeneration Research·Lun Zheng, Xigeng Zheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here